症状性颅内动脉粥样硬化性狭窄血管支架置入术后再狭窄的研究进展

摘要
图/表
参考文献(31)
相关文章 (15)

全文: PDF (0 KB) HTML (42 KB)
输出: BibTeX | EndNote (RIS)

摘要缺血性脑卒中指各种原因引起的局部脑组织供血动脉的血流障碍，导致脑组织缺血低氧性变性坏死，同时出现相应的临床神经功能缺失，是人类疾病谱中致残率最高的疾病之一，给患者家庭及整个社会都带来了沉重的负担。在缺血性脑卒中的TOAST 病因分型中，颅内大动脉粥样硬化引起的颅内动脉狭窄约占比例17.3%，在该类型中血管内介入治疗得到了广泛应用。随着血管内支架治疗的不断开展，支架内再狭窄（ISR）等远期并发症也越来越受到关注。本文在近年来国内外研究的基础上，对ISR 的发生率、发生机制、危险因素、评估方法、应对措施等方面进行综述，以期为颅内不同血管内支架治疗的安全性及有效性提供辅证，并在颅内动脉粥样硬化性缺血性卒中治疗方式的选择及患者围术期和远期管理上提供帮助。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	彭玮
	罗海彦

关键词 ：支架内再狭窄, 颅内动脉粥样硬化, 缺血性脑卒中, 支架置入术

Abstract：Ischemic stroke refers to the disturbance of blood flow in the blood supply artery of the local brain tissue caused by various reasons, which leads to the ischemic hypoxic degeneration and necrosis of the brain tissue. At the same time, the corresponding clinical neurological function loss occurs. It is one of the diseases with the highest disability rate in the human disease spectrum, which brings heavy burden to the patients′ family and the whole society. In the TOAST etiology classification of ischemic stroke, the proportion of intracranial artery stenosis caused by large intracranial atherosclerosis is about 17.3%, in which intravascular interventional therapy has been widely used. With the development of stent therapy, long-term complications such as in-stent restenosis (ISR) have attracted more and more attention. On the basis of the research at home and abroad in recent years, this paper reviews the incidence, mechanism, risk factors, assessment methods and Countermeasures of ISR, so as to provide evidence for the safety and effectiveness of different intracranial endovascular stent therapy, and to provide help in the selection of treatment methods of intracranial atherosclerotic ischemic stroke and the perioperative and long-term management of patients.

Key words： In-stent restenosis Atherosclerotic stenosis Ischemic stroke Stent implantation

基金资助:重庆市卫生适宜技术推广项目（2016jstg014）

引用本文:

彭玮；罗海彦. 症状性颅内动脉粥样硬化性狭窄血管支架置入术后再狭窄的研究进展[J]. 中国当代医药, 2020, 27(7): 21-24.
PENG Wei； LUO Hai-yan. Research progress of in-stent restenosis after stent implantation in symptomatic atherosclerotic intracranial stenosis. 中国当代医药, 2020, 27(7): 21-24.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I7/21

[1]	Zhao D，Liu J，Wang W，et al.Epidemiological transition of stroke in China：twenty-one-year observational study from the Sino-MONICA-Beijing Project[J].Stroke，2008，39（6）：1668-1674.
[6]	Weisberg LA.Clinical characteristics of transient is chemic attacks in black patients[J].Neurology，1991，41（9）：1410.
[8]	Wong LKS.Global burden of intracranial atherosclerosis[J].Int J Stroke，2006，1（3）：158-159.
[10]	支晓东，石向群.颅内动脉狭窄支架置入后对脑动脉及其供血脑组织影响的研究进展[J].中国脑血管病杂志，2014，11（7）：385-388.
[2]	Holmstedt CA，Turan TN，Chimowitz MI.Atherosclerotic intracranial arterial stenosis：risk factors，diagnosis，and treatment[J].Lancet Neurol，2013，12（11）：1106-1114.
[3]	Gorelick PB，Wong KS，Bae HJ，et al.Large artery intracranial occlusive disease：a large worldwide burden but a relatively neglected frontier[J].Stroke，2008，39（8）：2396-2399.
[4]	Sacco RL，Kargman DE，Gu Q，et al.Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction：the Northern Manhattan Stroke Study[J].Stroke，1995，26（1）：14-20.
[5]	Qureshi AI，Safdar K，Patel M，et al.Stroke in young black patients：risk factors，subtypes，and prognosis[J].Stroke，1995，26（11）：1995-1998.
[7]	Wityk RJ，Lehman D，Klag M，et al.Race and sex differences in the distribution of cerebral atherosclerosis[J].Stroke，1996，27（11）：1974-1980.
[9]	Zhou M，Wang H，Zhu J，et al.Cause-specific mortality for 240 causes in China during 1990～2013：a systematic subnational analysis for the Global Burden of Disease Study 2013[J].The Lancet，2016，387（10015）：251-272.
[11]	Morice MC，Colombo A，Meier B，et al.Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions：the REALITY trial：a randomized controlled trial [J].Jama，2006，295（8）：895-904.
[12]	Mehran R，Dangas G，Abizaid AS，et al.Angiographic patterns of in-stent restenosis：classification and implications for long-term outcome[J].Circulation，1999，100（18）：1872-1878.
[13]	Koh W，Kallenberg K，Karch A，et al.Transcranial doppler sonography is not a valid diagnostic tool for detection of basilar artery stenosis or in-stent restenosis：a retrospective diagnostic study[J].BMC Neurol，2017，17（1）：89.
[14]	Elwertowski M，Ma1ek G.Standards of the Polish Ultrasound Society-update.Examination of extracranial carotid and vertebral arteries[J].J Ultrason，2014，14（57）：179.
[15]	Madycki G，Gabriel M，Hawro P，et al.Duplex Doppler ultrasound examination of carotid and vertebral arteries：guidelines of the Polish Society for Vascular Surgery[J].Kardiol Pol，2014，72（3）：288-309.
[16]	AbuRahma AF，AbuRahma ZT，Scott G，et al.The incidence of carotid in-stent stenosis is underestimated ≥50% or≥80% and its clinical implications[J].J Vasc Surg，2019，69（6）：1807-1814.
[17]	Moon K，Alb uquerque FC，Levitt MR，et al.The myth of restenosis after carotid angioplasty and stenting[J].J Neurointerv Surg，2016，8（10）：1006-1010.
[18]	Ronchey S，Praquin B，Orrico M，et al.Outcomes of 1000 carotid Wallstent implantations：single-center experience[J].J Endovasc Ther，2016，23（2）：267-274.
[19]	Chen W，Huang F，Li M，et al.Incidence and Predictors of the In-stent restenosis after vertebral artery ostium stenting[J].J Stroke Cerebrovasc Dis，2018，27（11）：3030-3035.
[20]	Zheng D，Mingyue Z，Wei S，et al.The incidence and risk factors of in -stent restenosis for vertebrobasilar artery stenting[J].World Neurosurg，2018，110：e937-e941.
[21]	Waksman R，Iantorno M.Refractory in-stent restenosis：improving outcomes by standardizing our approach[J].Curr Cardiol Rep，2018，20（12）：140.
[22]	Yamashita K，Kokuzawa J，Kuroda T，et al.In-stent hypodense area at two weeks following carotid artery stenting predicts neointimal hyperplasia after two years[J].Neuroradiol J，2018，31（3）：280-287.
[23]	Tsuji Y，Koide M，Katsura K，et al.In-stent restenosis with“Inflammatory” neointima following everolimus -eluting stent implantation[J].Int Heart J，2018，59（5）：1142-1145.
[24]	Kayssi A，Al-Jundi W，Papia G，et al.Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries：protocols [Z]//Cochrane Database of Systematic Reviews.John Wiley & Sons，Ltd，2017.
[25]	Ye G，Yin X，Yang X，et al.Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease：a systematic review and meta-analysis[J].J Clin Neurosci，2019，59：112-118.
[26]	Clark DJ，Lessio S，O′Donoghue M，et al.Mechanisms and predictors of carotid artery stent restenosis：a serial intravascular ultrasound study[J].J Am Coll Cardiol，2006，47（12）：2390-2396.
[27]	Shi R，Zhang R，Yang F，et al.Tissue Kallikrein prevents restenosis after stenting of severe atherosclerotic stenosis of the middle cerebral artery：a randomized controlled trial[J].Medicine，2016，95（6）：e2809.
[28]	Yang WJ，Fisher M，Zheng L，et all.Histological characteristics of intracranial atherosclerosis in a Chinese population：a postmortem study[J].Front Neurol，2017，8：488.
[29]	Thiel WH，Esposito CL，Dickey DD，et al.Smooth muscle cell-targeted RNA aptamer inhibits neointimal formation[J].Mol Ther，2016，24（4）：779-787.
[30]	吴中华，仇汉诚，胡苏姗，等.症状性颅内支架内再狭窄的介入治疗[J].中华医学杂志，2018，98（37）：3017-3020.
[31]	Stilo F，Sirignano P，Montelione N，et al.Bypass for symptomatic in-stent carotid restenosis[J].Int J Cardiol，2017，249：392-395.